Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma


30 Sep 2019


Poster Display session 3


Tumour Site



Piotr Rutkowski


Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255


P. Rutkowski1, P. Pauwels2, J. Kerger3, B. Jacobs4, G.G. Maertens5, V. Gadeyne6, S. Liebert7, B. Neyns8

Author affiliations

  • 1 Department Of Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska Curie Institute - Oncology Centre (MSCI), 02-781 - Warsaw/PL
  • 2 Pathology, University Hospital Antwerp (UZA), 2650 - Edegem/BE
  • 3 Medical Oncology, Institute Jules Bordet, 1000 - Brussels/BE
  • 4 None, Biocartis NV Generaal de Wittelaan, 2800 - Mechelen/BE
  • 5 R&d, Biocartis, 2800 - Mechelen/BE
  • 6 R&d, NV Roche, CE-1070 - Brussels/BE
  • 7 R&d, NV Roche, BE-1070 - Brussels/BE
  • 8 Department Of Medical Oncology, Vrije Universiteit Brussel-Campus Jette, 1090 - Brussels/BE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2435


BRAF V600 mutations occur in 40-50% of metastatic melanomas as the most common "oncogenetic driver" event. Currently, BRAF V600 mutation status is assessed on tumor tissue to identify patients eligible for treatment with a BRAF+/-MEK inhibitor. The goal of this study is to estimate the frequency of the BRAF V600 mutation in a new tumor tissue analysis triggered by a mutant plasma test result, for patients with BRAF wild-type status based on a prior tissue test.


This is a single arm, multicenter, open label, non-randomized Phase II clinical study in adult patients with unresectable/metastatic melanoma. Patients were tested for the presence of BRAF V600 mutation using the IdyllaTM diagnostic platform on plasma cfDNA. In patients with a prior tissue BRAF V600 wild-type result, a mutant BRAF V600 plasma result triggered a new tissue analysis. The study had a power of 90% to reject the null hypothesis of a 3% probability of identifying the BRAFV600 mutation in case the real probability is 10%.


172 patients with known tissue test results were included (9.3% unresectable Stage IIIc and 90.7% Stage IV). The median time since diagnosis of metastatic melanoma was 19.3 (range: 0–268)) months. In 7 out of 118 patients (5.9%), previously determined as wild type BRAF V600 based on a tumor tissue test, a BRAF V600 mutation was found upon plasma cfDNA testing. In 5 of these 7 patients, presence of a BRAF V600 mutation could be confirmed in the tissue re-test. For 4.2% (5/118) the mutation could be shown in a re-test triggered by the mutant plasma cfDNA result. The one-sided test comparing this frequency with the a priori hypothesis of 3% was not significant (p = 0.215).


In 4.2% of the patients a known BRAF V600 wild-type status could be converted in a positive mutant status by retesting tumor tissue triggered by detection of a BRAF V600 mutation in cfDNA. Some patients could therefore benefit from plasma testing at the time of therapeutic decision making, although their number was not significantly more than the a priori required 3%. Identifying a BRAFwt subpopulation with the highest chance of having a BRAF V600mut cfDNA test result at the time of treatment decision making deserves further study.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study





P. Rutkowski: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (self): Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: BMS; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony, Research grant / Funding (self), Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pierre Fabre; Advisory / Consultancy: Blueprint Medicines; Speaker Bureau / Expert testimony: Eli Lilly. B. Jacobs: Full / Part-time employment: Biocartis. G.G. Maertens: Full / Part-time employment: Biocartis. V. Gadeyne: Full / Part-time employment: Roche. S. Liebert: Full / Part-time employment: Roche. B. Neyns: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Honoraria (institution): Merck Srono; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: BMS; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (institution): Merck Serono; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.